Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

FRACTYL HEALTH, INC. (GUTS) Financial Statements

FRACTYL HEALTH, INC. (GUTS) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$105.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$82.4M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GUTSFRACTYL HEALTH, INC.Follow GUTS — free
Medical Instruments & Supplies · Healthcare
—
Price chart with a free account
Market cap
14.3M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
11 Nov, in 18 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue0.10.0—
Gross profit0.00.0—
Research & development70.574.563.4
Operating income-93.5-96.8-85.9
Pre-tax income-68.7-141.0-105.7
Income tax0.00.0—
Net income-68.7-141.0-105.7
Diluted EPS ($)-19.44-22.32-8.00
Diluted shares (mn)3.66.3—

USD millions · SEC XBRL

FRACTYL HEALTH, INC. — questions

What is FRACTYL HEALTH, INC.'s revenue?
$0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
What is FRACTYL HEALTH, INC.'s net income?
-$105.7M over the twelve months to 2026-06-30.
What is FRACTYL HEALTH, INC.'s free cash flow?
-$82.4M over the twelve months to 2026-06-30.
What are FRACTYL HEALTH, INC.'s diluted earnings per share?
$-8.00 over the twelve months to 2026-06-30.

Every figure on this page comes from FRACTYL HEALTH, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.